VLX1570   Click here for help

GtoPdb Ligand ID: 9413

Synonyms: VLX-1570
Compound class: Synthetic organic
Comment: VLX1570 is a competitive, reversible inhibitor of 19S proteasome-specific deubiquitylating enzymes, including ubiquitin specific protease 14 (USP14) and ubiquitin C-terminal hydrolase L5 (UCHL5) [1-2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 0
Rotatable bonds 6
Topological polar surface area 123.66
Molecular weight 469.4
XLogP 1.8
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C=CC(=O)N1CC/C(=C\C2=CC=C(C(=C2)[N+](=O)[O-])F)/C(=O)/C(=C/C3=CC=C(C(=C3)[N+](=O)[O-])F)/C1
Isomeric SMILES C=CC(=O)N1CC/C(=C\C2=CC(=C(C=C2)F)[N+](=O)[O-])/C(=O)/C(=C/C3=CC(=C(C=C3)F)[N+](=O)[O-])/C1
InChI InChI=1S/C23H17F2N3O6/c1-2-22(29)26-8-7-16(9-14-3-5-18(24)20(11-14)27(31)32)23(30)17(13-26)10-15-4-6-19(25)21(12-15)28(33)34/h2-6,9-12H,1,7-8,13H2/b16-9+,17-10+
InChI Key SCKXBVLYWLLALY-CZCYGEDCSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
VLX1570 was progressed as a clinical candidate for the treatment of relapsed/refractory multiple myeloma. Development was terminated due to treatment-induced severe lung toxicity.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
USP14 is the preferential target of VLX1570 inhibition [1]. Exposure to VLX1570 leads to an accumulation of poly-ubiquitylated proteins, which promotes tumour cell apoptosis and inhibits tumour cell proliferation via induction of the unfolded protein response (UPR).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02372240 A Study of VLX1570 and Dexamethasone in Myeloma Patients Phase 1/Phase 2 Interventional Vivolux AB